219 related articles for article (PubMed ID: 34019124)
1. Cross-sectional adherence with the multi-target stool DNA test for colorectal cancer screening in a large, nationally insured cohort.
Miller-Wilson LA; Rutten LJF; Van Thomme J; Ozbay AB; Limburg PJ
Int J Colorectal Dis; 2021 Nov; 36(11):2471-2480. PubMed ID: 34019124
[TBL] [Abstract][Full Text] [Related]
2. Cross-sectional adherence with the multi-target stool DNA test for colorectal cancer screening in a medicaid population.
Miller-Wilson LA; Finney Rutten LJ; Van Thomme J; Burak Ozbay A; Laffin J; Limburg P
Prev Med Rep; 2022 Dec; 30():102032. PubMed ID: 36531112
[TBL] [Abstract][Full Text] [Related]
3. Cross-sectional adherence with the multi-target stool DNA test for colorectal cancer screening: Real-world data from a large cohort of older adults.
Weiser E; Parks PD; Swartz RK; Thomme JV; Lavin PT; Limburg P; Berger BM
J Med Screen; 2021 Mar; 28(1):18-24. PubMed ID: 32054393
[TBL] [Abstract][Full Text] [Related]
4. Real-world cost-effectiveness of stool-based colorectal cancer screening in a Medicare population.
Fisher DA; Karlitz JJ; Jeyakumar S; Smith N; Limburg P; Lieberman D; Fendrick AM
J Med Econ; 2021; 24(1):654-664. PubMed ID: 33902366
[TBL] [Abstract][Full Text] [Related]
5. Multitarget stool DNA tests increases colorectal cancer screening among previously noncompliant Medicare patients.
Prince M; Lester L; Chiniwala R; Berger B
World J Gastroenterol; 2017 Jan; 23(3):464-471. PubMed ID: 28210082
[TBL] [Abstract][Full Text] [Related]
6. Alaska Native Patient and Provider Perspectives on the Multitarget Stool DNA Test Compared With Colonoscopy for Colorectal Cancer Screening.
Redwood DG; Blake ID; Provost EM; Kisiel JB; Sacco FD; Ahlquist DA
J Prim Care Community Health; 2019; 10():2150132719884295. PubMed ID: 31646933
[No Abstract] [Full Text] [Related]
7. Estimated impact and value of blood-based colorectal cancer screening at varied adherence compared with stool-based screening.
Kisiel JB; Fendrick AM; Ebner DW; Ozbay AB; Vahdat V; Estes C; Limburg PJ
J Med Econ; 2024; 27(1):746-753. PubMed ID: 38686394
[TBL] [Abstract][Full Text] [Related]
8. Estimating the impact of differential adherence on the comparative effectiveness of stool-based colorectal cancer screening using the CRC-AIM microsimulation model.
Piscitello A; Saoud L; Fendrick AM; Borah BJ; Hassmiller Lich K; Matney M; Ozbay AB; Parton M; Limburg PJ
PLoS One; 2020; 15(12):e0244431. PubMed ID: 33373409
[TBL] [Abstract][Full Text] [Related]
9. Evaluating Outreach Methods for Multi-Target Stool DNA Test for Colorectal Cancer Screening Among an Employer Population.
Shepherd ME; Lecorps A; Harris-Shapiro J; Miller-Wilson LA
J Prim Care Community Health; 2021; 12():21501327211037892. PubMed ID: 34382887
[TBL] [Abstract][Full Text] [Related]
10. The cost-effectiveness of non-invasive stool-based colorectal cancer screening offerings from age 45 for a commercial and medicare population.
Ebner D; Kisiel J; Barnieh L; Sharma R; Smith NJ; Estes C; Vahdat V; Ozbay AB; Limburg P; Fendrick AM
J Med Econ; 2023; 26(1):1219-1226. PubMed ID: 37752872
[TBL] [Abstract][Full Text] [Related]
11. Analysis of the effectiveness of two noninvasive fecal tests used to screen for colorectal cancer in average-risk adults.
Sharma T
Public Health; 2020 May; 182():70-76. PubMed ID: 32179290
[TBL] [Abstract][Full Text] [Related]
12. Lowering the colorectal cancer screening age improves predicted outcomes in a microsimulation model.
Fisher DA; Saoud L; Finney Rutten LJ; Ozbay AB; Brooks D; Limburg PJ
Curr Med Res Opin; 2021 Jun; 37(6):1005-1010. PubMed ID: 33769894
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Simulated Outcomes Between Stool- and Blood-Based Colorectal Cancer Screening Tests.
Fendrick AM; Vahdat V; Chen JV; Lieberman D; Limburg PJ; Ozbay AB; Kisiel JB
Popul Health Manag; 2023 Aug; 26(4):239-245. PubMed ID: 37466476
[TBL] [Abstract][Full Text] [Related]
14. Impact of Patient Adherence to Stool-Based Colorectal Cancer Screening and Colonoscopy Following a Positive Test on Clinical Outcomes.
Fendrick AM; Fisher DA; Saoud L; Ozbay AB; Karlitz JJ; Limburg PJ
Cancer Prev Res (Phila); 2021 Sep; 14(9):845-850. PubMed ID: 34021023
[TBL] [Abstract][Full Text] [Related]
15. Healthcare costs, resource utilization, and productivity loss associated with colorectal cancer screening.
Engel-Nitz NM; Miller-Wilson LA; Le L; Fisher DA
Expert Rev Pharmacoecon Outcomes Res; 2023; 23(7):843-852. PubMed ID: 37462667
[TBL] [Abstract][Full Text] [Related]
16. The health economic impact of varying levels of adherence to colorectal screening on providers and payers.
Hathway JM; Miller-Wilson LA; Yao W; Jensen IS; Weinstein MC; Parks PD
J Med Econ; 2021; 24(1):69-78. PubMed ID: 33970747
[TBL] [Abstract][Full Text] [Related]
17. Specificity of the Multi-Target Stool DNA Test for Colorectal Cancer Screening in Average-Risk 45-49 Year-Olds: A Cross-Sectional Study.
Imperiale TF; Kisiel JB; Itzkowitz SH; Scheu B; Duimstra EK; Statz S; Berger BM; Limburg PJ
Cancer Prev Res (Phila); 2021 Apr; 14(4):489-496. PubMed ID: 33436397
[TBL] [Abstract][Full Text] [Related]
18. Comparative Effectiveness and Cost Effectiveness of a Multitarget Stool DNA Test to Screen for Colorectal Neoplasia.
Ladabaum U; Mannalithara A
Gastroenterology; 2016 Sep; 151(3):427-439.e6. PubMed ID: 27311556
[TBL] [Abstract][Full Text] [Related]
19. USPSTF colorectal cancer screening guidelines: an extended look at multi-year interval testing.
Berger BM; Parton MA; Levin B
Am J Manag Care; 2016 Feb; 22(2):e77-81. PubMed ID: 26881323
[TBL] [Abstract][Full Text] [Related]
20. Colorectal cancer screening uptake and adherence by modality at a large tertiary care center in the United States: a retrospective analysis.
Cheney C; Parish A; Niedzwiecki D; Oko C; Walters C; Halpern D; Helmueller L; Hoyek NE; Miller-Wilson LA; Sullivan BA
Curr Med Res Opin; 2024 Mar; 40(3):431-439. PubMed ID: 38197407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
